ClinicalTrials.Veeva

Menu

A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder

Allergan logo

Allergan

Status and phase

Terminated
Phase 2

Conditions

Depressive Disorder, Major

Treatments

Drug: Rapastinel
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT03352453
RAP-MD-20

Details and patient eligibility

About

The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) of Rapastinel, compared to placebo in adult patients with major depressive disorder (MDD) who are at imminent risk of suicide.

Enrollment

138 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Meet Diagnostic and Statistical Manual of Mental Disorders - Fifth Edition (DSM-5) criteria for MDD
  • Current major Depressive episode of at least 4 weeks and not exceeding 24 months in duration at visit 1
  • Have current, ongoing suicidality (ideation or behavior) of sufficient severity to warrant hospitalization based on the judgment of the investigator
  • If female of childbearing potential, have a negative serum β-human chorionic gonadotropin (β-hCG) pregnancy test.

Exclusion criteria

  • DSM-5-based diagnosis of any disorder other than MDD that was the primary focus of treatment within 1 month before Visit 1.

  • Lifetime history or currently meet DSM-5 criteria for:

    1. Schizophrenia spectrum or other psychotic disorder
    2. Bipolar or related disorder
    3. Major neurocognitive disorder
    4. Neurodevelopmental disorder of greater than mild severity or of a severity that impacts the participant's ability to consent, follow study directions, or otherwise safely participate in the study.
    5. Dissociative disorder
    6. Posttraumatic stress disorder
    7. MDD with psychotic features
  • Significant homicidal ideation or at imminent risk of injuring others or causing significant damage to property, as judged by the investigator.

  • Prior participation in any investigational study of rapastinel/GLYX-13

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

138 participants in 2 patient groups, including a placebo group

Rapastinel 450mg
Experimental group
Description:
Rapastinel 450 milligram (mg) weekly intravenous (IV) injections.
Treatment:
Drug: Rapastinel
Placebo
Placebo Comparator group
Description:
Placebo-matching rapastinel weekly IV injections.
Treatment:
Drug: Placebo

Trial documents
2

Trial contacts and locations

17

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems